EOM Pharmaceutical Holdings Provides an Update on Its Lead Drug Candidate EOM613

MONTVALE, N.J., Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a pep

PR NewswireNov 7, 2023 07:00 ET

EOM Pharmaceutical Holdings Announces Topline Results of Its COVID-19 Clinical Trial of EOM613 in Brazil

Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J., Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings,

PR NewswireSep 6, 2023 07:00 ET

IPO Roundup: Richtech Robotics, Triller and More

Seeking AlphaAug 7, 2023 08:47 ET

EOM Pharmaceuticals Shelves Plans to Uplist Shares, Raise $15M

Seeking AlphaAug 3, 2023 18:01 ET

EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR THERAPEUTICS, LTD.

Company to continue trading on the OTC Markets under the ticker symbol "IMUC" while pursuing listing on a national exchange MONTVALE, N.J., Nov. 10, 2022 /PRNewswire/ -- EOM Pharmaceutical Holdings,

PR NewswireNov 10, 2022 10:12 ET

EOM Pharmaceuticals files to uplist to Nasdaq

EOM Pharmaceuticals (OTCPK:IMUC) has filed to uplist from the Pink Sheets to the Nasdaq. As part of the application, EOM would trade on the Nasdaq under the ticker "EOM." EOM (formerly ImmunoCellular

Seeking AlphaJun 24, 2022 17:08 ET